Clinical trials: Mismatch Repair-deficient (dMMR)
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in…
- Conditions
- Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
- Trial name
- NCT07262619
- Testing
- EIK1005, pembrolizumab (KEYTRUDA® )
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 160 people
- Sponsor
- Eikon Therapeutics
Endometrial Cancer
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
The researchers are doing this study to evaluate the use of circulating tumor DNA (ctDNA) testing in making treatment decisions for advanced/recurrent endometrial cancer that has a change (mutation) in the mismatch repair…
- Trial name
- NCT07270666
- Testing
- ctDNA Testing, Blood draw, Surveys
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer (MSI-H), Colorectal Cancer (CRC)
Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer
Patients with clinical stage II-III dMMR/MSI colorectal adenocarcinoma will be treated with low-dose immunotherapy: nivolumab 100 mg or pembrolizumab 100 mg. The duration of treatment is 6 months.
- Trial name
- NIVO1002024 (NCT07523763)
- Testing
- Nivolumab, Pembrolizumab
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors
MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastrointestinal Cancers
Lymph node metastasis (LNM) is a key factor influencing treatment decisions and prognosis in patients with gastric cancer. Lymphatic invasion (LI) is an important pathological predictor of LNM and a core component of the eCURA…
- Conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors, Lymph Node Metastasis, Lymphatic Invasion
- Trial name
- NCT07625735
- Testing
- Mismatch repair (MMR) status, Lymphatic invasion status
- Volunteers
- 5,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Neurofibromatosis Type 1
Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation
Frequency of constitutional mismatch-repair deficiency among suspected neurofibromatosis type 1 patients without a NF1 mutation Constitutional mismatch repair deficiency (CMMRD) is a rare inherited condition.
- Trial name
- CMMRD in NF1 (NCT03757247)
- Volunteers
- 670 people
- Sponsor
- Medical University Innsbruck
Colorectal Cancer
Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer
Colorectal cancer is one of the most common malignant tumors, accounting for approximately 10% of new cancer cases and cancer-related deaths worldwide each year.
- Trial name
- NCT06698757
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Yugui Lian
Advanced Solid Tumors
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite…
- Trial name
- NCT07208136
- Testing
- JMKX005425
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Jemincare
Colorectal Cancer
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin
The investigators hypothesize that atezolizumab will improve the prognosis of patients with stage III dMMR CRC ineligible for or refusing oxaliplatin-based adjuvant chemotherapy compared to SOC and that these could therefore be…
- Trial name
- ANTONIO (NCT05118724)
- Testing
- Atezolizumab, IMM-101
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- AIO-Studien-gGmbH
Colorectal Cancer, Mismatch Repair-deficient (dMMR)
Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer
This study will evaluate the safety, and tolerability of Cadonilimab as neoadjuvant treatment for resectable local advanced colorectal cancer patient with dMMR/MSI-H.
- Conditions
- Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
- Trial name
- MSI-H/dMMR (NCT05913570)
- Testing
- Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
- Where
- China
- Volunteers
- 22 people
- Sponsor
- LiuYing
Prostate Cancer, Recurrent Prostate Cancer
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
MMR-deficient cancers of any histologic type appear to be very sensitive to PD-1 blockade with pembrolizumab, and similar data are also beginning to emerge for nivolumab and other immune checkpoint inhibitors.
- Trial name
- NCT04019964
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Endometrial Cancer, Solid Tumors
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
This is a study of pembrolizumab in combination with sitravatinib in adult women with recurrent endometrial cancer or other solid tumors with deficient mismatch repair system.
- Trial name
- NCT05419817
- Testing
- pembrolizumab, Sitravatinib
- Sponsor
- Haider Mahdi
Endometrial Cancer
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial cancer.
- Trial name
- DOMENICA (NCT05201547)
- Testing
- Carboplatin-Paclitaxel, Dostarlimab
- Where
- 100 sites in Australia, Canada and 8 more
- Volunteers
- 260 people
- Sponsor
- ARCAGY/ GINECO GROUP
Colorectal Tumors, Colorectal Neoplasms
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
Background: Colorectal cancer is a common cancer in the Unites States (U.S.) It causes the second most cancer-related deaths. The drug avelumab and vaccine Ad-CEA together help the immune system fight cancer.
- Conditions
- Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma
- Trial name
- NCT03050814
- Testing
- Avelumab, Ad-CEA vaccine, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic, Mismatch Repair Deficiency
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) accounts for 4-5% in metastatic colorectal cancer (mCRC).
- Conditions
- Colorectal Cancer Metastatic, Mismatch Repair Deficiency, Microsatellite Instability High
- Trial name
- NCT04482608
- Where
- China
- Volunteers
- 671 people
- Sponsor
- Sun Yat-sen University
MSI-H/dMMR Solid Tumors
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high…
- Trial name
- NCT03736889
- Testing
- Tislelizumab (BGB-A317)
- Where
- 29 sites in China
- Volunteers
- 200 people
- Sponsor
- BeiGene
Epstein-Barr Virus Positive, Gastric Adenocarcinoma
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
This phase II trial studies how well pembrolizumab works with capecitabine and radiation therapy in treating patients with mismatch repair deficient and Epstein-Barr virus positive gastric cancer.
- Conditions
- Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency, Stage IB Gastric Cancer AJCC v7
- Trial name
- NCT03257163
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rutgers, The State University of New Jersey
Uterine Cancer, Endometrial Carcinoma
A Study of Nivolumab in Selected Uterine Cancer Patients
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer.
- Conditions
- Uterine Cancer, Endometrial Carcinoma, Carcinosarcoma, Leiomyosarcoma
- Trial name
- NCT03241745
- Testing
- Nivolumab
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer (MSI-H)
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
This phase II clinical trial evaluates the efficacy and safety of three neoadjuvant regimens in patients with locally advanced microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC): 1)…
- Trial name
- TORCH-OPTIMA (NCT07403877)
- Testing
- Nivolumab, Ipilimumab (1mg/kg), PULSAR
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Fudan University
Gastric Cancer
Sintilimab Combined With LDRT for Neoadjuvant Treatment of Locally Advanced dMMR/MSI-H Gastric Cancer
Recently, growing evidences have suggested that immunotherapy represents a promising treatment option for the neoadjuvant treatment of locally advanced mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H)…
- Trial name
- NCT06426654
- Testing
- sintiliman plus LDRT
- Volunteers
- 45 people
- Sponsor
- West China Hospital
Adenocarcinoma - GEJ, Gastric Adenocarcinoma
DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study
This phase II study evaluates dostarlimab followed by a watch-and-wait strategy in patients with localized dMMR/MSI-H gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- DEWI (NCT06059495)
- Testing
- Dostarlimab
- Where
- 18 sites in France, Italy
- Volunteers
- 89 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group